N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: Comparison with patients in different stages of heart failure

Clinical Chemistry

Volumn 51, Issue 1, 2005, Pages 138-143

  Hermann Arnhof, Katharina Maria ^a   Hanusch Enserer, Ursula ^b   Kaestenbauer, Thomas ^a   Publig, Thomas ^a   Dunky, Attila ^b   Rosen, Harald R ^c   Prager, Rudolf ^a   Köller, Ursula ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

^b Division of Rheumatology   (Austria)

^c Danubehospital SMZO   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANAMNESIS; ARTICLE; BLOOD CHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL EXAMINATION; PROGNOSIS; THORAX RADIOGRAPHY;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; OBESITY; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 11144270162     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.035923     Document Type: Article

References (35)

1. Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002;288:1758-61.
2. Kannel WB, Wilson PW, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002;90:697-701.
3. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996;93:1372-9.
4. Kearney MT, Marber M. Trends in incidence and prognosis of heart failure; you always pass failure on the way to success. Eur Heart J 2004;25:283-4.
5. Pantilat SZ, Steimle AE. Palliative care for patients with heart failure. JAMA 2004;291:2476-82.
6. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002;162:1477-81.
7. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S15-20.
8. Crisostomo LL, Araujo LM, Camara E, Carvalho C, Silva FA, Vieira M, et al. Left ventricular mass and function in young obese women. Int J Obes Relat Metab Disord 2001;25:233-8.
9. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003;16:41S-5S.
10. Skiles JA, Griffin BP. Transesophageal echocardiographic (TEE) evaluation of ventricular function. Cardiol Clin 2000;18:681-97, vii.
11. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004;43:1399-404.
12. Wong M, Tavazzi L. Effect of drug therapy for heart failure on quality of life. J Clin Hypertens (Greenwich) 2004;6:256-61.
13. O'Brien PE, Dixon JB. The extent of the problem of obesity. Am J Surg 2002;184:4S-8S.
14. Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6:295-300.
15. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 2001;321:242-8.
16. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mahr B, Dunky A, et al. Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res 2003;11:695-8.
17. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:11-22.
18. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003;49:976-9.
19. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001;142:725-32.
20. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
21. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
22. Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004;50:1174-83.
23. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004;6:351-4.
24. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
25. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004;6:289-93.
26. Wendelboe Nielsen O, Kirk V, Bay M, Boesgaard S, Nielsen H. Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Eur J Heart Fail 2004;6:275-9.
27. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ 2000;320:220-4.
28. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.
29. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
30. Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, et al. Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur J Clin Invest 2004;34:342-8.
31. Jaarsma T, Stewart S, De Geest S, Fridlund B, Heikkila J, Martensson J, et al. A survey of coronary risk factors and B-type natriuretic peptide concentrations in cardiac nurses from Europe: do nurses still practice what they preach? Eur J Cardiovasc Nurs 2004;3:3-6.
32. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 2003;49:1560-2.
33. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AH, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004;340:163-72.
34. Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000;38:519-23.
35. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci (Lond) 1999;97:689-95.